STOCK TITAN

Amphastar (AMPH) Form 144: Proposed Sale of 500 Shares via UBS on NASDAQ

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

  • Disclosure compliance: Proposed sale and recent transactions are reported on Form 144 using a registered broker (UBS).
  • Traceable acquisition: Shares were acquired as RSUs on 06/07/2022, and acquisition details are provided.

Negative

  • Insider selling activity: The filer sold 1,500 shares in the past three months and proposes to sell another 500 shares, which may be viewed negatively by some investors.
  • Missing context: The filing does not state the filer’s relationship to the issuer or provide a 10b5-1 plan adoption date.

Insights

TL;DR: Modest insider sales disclosed; proposed sale is small relative to total outstanding shares.

The filing shows a planned sale of 500 shares and prior sales totaling 1,500 shares. With 46,495,077 shares outstanding the transactions are immaterial to company capitalization. Disclosure via Form 144 and use of a registered broker (UBS) indicate compliance with Rule 144 procedures. No purchase plan date or relationship to the issuer is provided in the filing text, and there is no financial performance data in this notice to assess motivation.

TL;DR: Filing meets procedural requirements but lacks certain contextual details about relationship to issuer.

The document supplies acquisition details (RSU grant date 06/07/2022), broker information, and past sale records, supporting traceability for transfer compliance. The signer affirms absence of undisclosed material adverse information, which is standard. The filing does not state the filer’s relationship to the issuer or any 10b5-1 plan adoption date, limiting assessment of planned trading safeguards.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for AMPH disclose?

The Form 144 discloses a proposed sale of 500 common shares via UBS on NASDAQ around 09/02/2025, acquired as RSUs on 06/07/2022.

How many shares has the filer sold in the past three months for AMPH?

The filer sold three tranches totaling 1,500 shares on 06/02/2025, 07/02/2025, and 08/01/2025 with combined gross proceeds of $34,984.75.

What is the aggregate market value of the proposed AMPH sale?

The aggregate market value listed for the proposed sale of 500 shares is $15,450.00.

Who is handling the sale and where will the shares trade?

The broker listed is UBS Financial Services, Inc. and the securities are to be sold on NASDAQ.

How many shares outstanding does Amphastar report in the filing?

The filing lists 46,495,077 shares outstanding.
Amphastar Pharma

NASDAQ:AMPH

AMPH Rankings

AMPH Latest News

AMPH Latest SEC Filings

AMPH Stock Data

1.23B
34.79M
24.02%
71.85%
8.94%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
RANCHO CUCAMONGA